Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBITDA (2019 - 2025)

Historic EBITDA for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$15.4 million.

  • Keros Therapeutics' EBITDA rose 7377.3% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 12136.16%. This contributed to the annual value of -$210.8 million for FY2024, which is 2406.25% down from last year.
  • As of Q3 2025, Keros Therapeutics' EBITDA stood at -$15.4 million, which was up 7377.3% from -$39.8 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year EBITDA high stood at $152.0 million for Q1 2025, and its period low was -$58.7 million during Q3 2024.
  • Over the past 5 years, Keros Therapeutics' median EBITDA value was -$32.0 million (recorded in 2022), while the average stood at -$24.0 million.
  • As far as peak fluctuations go, Keros Therapeutics' EBITDA tumbled by 55680.23% in 2022, and later skyrocketed by 41359.45% in 2025.
  • Over the past 5 years, Keros Therapeutics' EBITDA (Quarter) stood at -$4.9 million in 2021, then crashed by 556.8% to -$32.0 million in 2022, then tumbled by 45.35% to -$46.5 million in 2023, then fell by 14.64% to -$53.3 million in 2024, then skyrocketed by 71.11% to -$15.4 million in 2025.
  • Its EBITDA was -$15.4 million in Q3 2025, compared to -$39.8 million in Q2 2025 and $152.0 million in Q1 2025.